Wednesday, 15 Aug 2018

You are here

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

COAST-W is a multicenter, randomized, double-blind, placebo-controlled 16-week study of the efficacy and safety of ixekizumab in active AS patients who were TNFi-IR.  Patients were treated with 80 mg of Taltz SC either every two weeks or every four weeks (following a 80 mg or 160 mg starting dose at Week 0), or placebo.  The primary efficacy endpoint was the proportion of patients at 16 weeks who achieved ASAS40 response.

The Taltz development program (COAST) in axial SpA (AS) includes the three different trials COAST-V (bDMARD-naïve), COAST-W (TNFi experienced), and COAST-X (non-radiographic axSpA who are bDMARD-naïve) studies . A long-term extension study will study patients for an additional two years. 

COAST-W trial showed superior (ASAS40) responses at 16 weeks compared to placebo treated patients. The incidence of serious adverse events was similar with Taltz compared with placebo. 

Ixekizumab is currently FDA approved for the treatment of adults with active psoriatic arthritis and adults with moderate-to-severe plaque psoriasis.

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Minimal Disease Activity: The Goal in PsA

The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

NPF Dietary Recommendations for Psoriatic Disease

The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.